<DOC>
	<DOCNO>NCT00377819</DOCNO>
	<brief_summary>The study evaluate efficacy safety transition postmenopausal woman current alendronate therapy denosumab . Endpoints study include bone mineral density , bone turnover marker bone histology subset subject .</brief_summary>
	<brief_title>Study Transitioning From Alendronate Denosumab</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Osteoporosis , Postmenopausal</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Postmenopausal females 55 yr old Received alendronate therapy osteoporosis least 6 month prior entry study Lumbar spine total hip Bone Mineral Density ( BMD ) correspond Tscore ≤ 2 ≥ 4 Vitamin D deficiency Administration intravenous bisphosphonate , fluoride ( except dental treatment ) strontium ranelate Administration Parathyroid Hormone ( PTH ) Parathyroid Hormone ( PTH ) derivative ( eg ; teriparatide ) within last year Administration bisphosphonate alendronate ( ALN ) within 1 year screening</criteria>
	<gender>Female</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>RANKL</keyword>
	<keyword>RANK</keyword>
	<keyword>denosumab</keyword>
	<keyword>AMG 162</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>bone turnover</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>clinical trial</keyword>
	<keyword>postmenopausal osteoporosis</keyword>
	<keyword>alendronate</keyword>
	<keyword>total hip bone mineral density</keyword>
</DOC>